Physician profile
Vadim Yuri Baram
NPI 1124007380
$1,863,371.14
in general payments reported to CMS, 2019-2025
47 companies · $517K in 2025
The $517K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299K · 2020: $105K · 2021: $185K · 2022: $205K · 2023: $352K · 2024: $200K · 2025: $517K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $864K · Travel and Lodging: $97K · Food and Beverage: $54K · Consulting Fee: $34K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $20K · Honoraria: $325 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $863,619.57 |
| Travel and Lodging | $96,895.73 |
| Food and Beverage | $53,923.08 |
| Consulting Fee | $34,463.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $19,503.75 |
| Honoraria | $325.00 |
| Education | $268.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $499,376.22 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $320,306.22 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $289,657.35 | 2019-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $247,055.72 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Avanir Pharmaceuticals, INC. | $189,070.10 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $82,978.13 | 2024-2025 | Cobenfy |
| Bioxcel Therapeutics, INC. | $56,269.58 | 2023 | Igalmi |
| Acadia Pharmaceuticals INC | $52,005.89 | 2019-2025 | Nuplazid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43,566.86 | 2020-2025 | Caplyta |
| Noven Pharmaceuticals, INC. | $14,597.73 | 2024 | Xelstrym |
| Axsome Therapeutics, INC. | $11,277.88 | 2022-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $9,790.01 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $9,758.80 | 2019-2022 | |
| Noven Therapeutics, LLC | $8,858.91 | 2020-2025 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $8,701.08 | 2019-2024 | Trintellix |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $7,894.48 | 2019-2024 | Perseris |
| Harmony Biosciences LLC | $1,995.40 | 2022-2025 | Wakix |
| Supernus Pharmaceuticals, INC. | $1,573.59 | 2022-2025 | Qelbree, Qelbree |
| Abbvie INC. | $1,460.75 | 2021-2025 | Vraylar |
| Bausch Health US, LLC | $1,421.99 | 2019-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $1,306.74 | 2020-2025 | Dyanavel Xr, Onyda Xr |
| Neos Therapeutics, Lp | $1,057.64 | 2021-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Jazz Pharmaceuticals INC. | $678.94 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $573.20 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $291.61 | 2024-2025 | Invega Sustenna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.65 | 2024 | Relistor |
| Eisai INC. | $214.01 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $195.74 | 2020-2023 | Belsomra |
| Luye Pharma (USA) Ltd. | $170.23 | 2025 | Erzofri Extended-Release |
| Idorsia Pharmaceuticals US INC | $169.62 | 2023 | Quviviq |
| Livanova USA, INC. | $163.21 | 2022-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Mdd US Operations, LLC | $137.80 | 2019 | |
| Ironshore Pharmaceuticals INC. | $136.57 | 2024 | |
| Novo Nordisk INC | $59.71 | 2023-2024 | Wegovy |
| Sage Therapeutics, LLC | $56.71 | 2024 | |
| Allergan, INC. | $50.00 | 2021 | |
| Almatica Pharma LLC | $49.44 | 2021-2024 | Gralise, Loreev Xr |
| Lilly USA, LLC | $44.15 | 2025 | Mounjaro, Zepbound, Kisunla |
| Vertical Pharmaceuticals, LLC | $35.98 | 2019-2025 | Relexxii |
| Alpha Cognition USA, INC. | $31.81 | 2025 | Zunveyl |
| Collegium Pharmaceutical, INC. | $19.95 | 2025 | Jornay Pm |
| Tms Neurohealth Centers INC. | $18.59 | 2025 | Tms Neurohealth Centers INC. |
| Braeburn INC. | $15.41 | 2024 | Brixadi |
| Sumitomo Pharma America, INC. | $14.89 | 2023 | |
| Shire North American Group INC | $14.65 | 2019 | |
| Aytu Biopharma, INC. | $13.05 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vadim Baram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.